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Highlights
Like other severe systemic infections,
malaria leads to stimulation of the
HPA axis, resulting in increased GC
levels.
The essential roles of GCs for disease
tolerance in malaria have been
largely overlooked. GCs are decisive
to survive malaria via the regulation
and integration of vital systemic pro-
cesses such as immune reactions,
metabolism, and vascular function.
Existing evidence of the function
and possible dysregulation of the
HPA axis in malaria is scarce, but
may hold the key to a better un-
derstanding and treatment of spe-
cific malaria complications.
The failure of clinical trials with GCs
against cerebral malaria preluded the
neglect of GCs in the malaria field,
but the therapeutic impact on other
complications or patient subsets is
unknown.During malaria, the hypothalamic–pituitary–adrenal (HPA) axis is activated and glucocorticoid
(GC) levels are increased, but their essential roles have been largely overlooked. GCs are deci-
sive for systemic regulation of vital processes such as immune responses, vascular function,
and metabolism, which are crucial in malaria. Here, we introduce GCs in general, followed by
their versatile roles for disease tolerance in malaria. A complementary comparison is provided
with their role in sepsis. Finally, potential translational implications are considered. The failed
clinical trials of dexamethasone against cerebral malaria in the past have diminished the interest
in GCs in malaria. However, the issue of relative corticosteroid insufficiency has barely been
explored in malaria patients, but may hold promise for a better understanding and treatment
of specific malaria complications.
Disease Tolerance in Malaria
Malaria is a parasitic disease that poses a major health burden to the world with an estimated
219 million cases and 435 000 deaths in 2017 [1]. The outcome of infection with Plasmodium ranges
from asymptomatic infection in semi-immune individuals to uncomplicated malaria (UM) and compli-
cated/severe malaria (SM). Complications of malaria contribute to the majority of deaths and include
cerebral malaria (CM), severe malarial anemia, placental malaria andmalaria-associated acute respi-
ratory distress syndrome (MA-ARDS) (see Glossary). The pathogenesis of malaria complications is
complex, with several processes taking part, such as parasite sequestration, endothelial activation,
and inflammation [2]. Metabolic disturbances, including hypoglycemia and lactic acidosis, are
common in malaria and contribute significantly to the severity of disease, but they remain poorly un-
derstood [3,4]. The pathophysiology of hypoglycemia in malaria is often explained by increased
glucose consumption by hypoxic tissues, the febrile host and the parasite, inadequate food intake,
and insufficient glucose production, possibly due to decreased liver perfusion [5].
Disease tolerance relies on host defense mechanisms that limit the pathological consequences of the
infection without interfering with the parasite load [6–8]. It remains unclear why some patients prog-
ress from UM to SM and lose their disease tolerance. Defining the mechanisms of tolerance in malaria
is extremely important, since these may help to design new treatments to combat the detrimental
progression of disease. Several studies indicate the importance of glucose metabolism in disease
tolerance tomalaria. Cumnock et al. suggested that, in a nonlethal murine model of malaria, the com-
bination of anorexia and severe anemia makes the host more reliant on glycolysis, which is essential
for survival [9]. Contrarily, in the lethal experimental cerebral malaria model, Wang et al. showed that
blocking glycolysis prolonged survival [10]. In general, the host nutritional status is important for the
outcome of infection. For instance, dietary restriction affects the host response to the parasite in the
spleen and liver [11,12]. Metabolic adaptations of the host were also associated with disease
tolerance in bacterial and viral infections [13,14]. Tolerance mechanisms in malaria include also
anti-inflammatory and pro-resolving processes that do not influence pathogen clearance but alleviate
immunopathology. For instance, in several models interleukin (IL)-10 protects malaria-infected mice
against lethal disease without decreasing peripheral parasitemia [15].
A severe systemic infection is stressful and induces a neuroendocrine response that aims to restore
homeostasis and thus to promote tolerance. One of the most essential responses is the activation
of the hypothalamic–pituitary–adrenal (HPA) axis that results in glucocorticoid (GC) production
[16]. Upon malaria infection, circulating GC levels increase (see Table S1 in the supplemental918 Trends in Parasitology, November 2019, Vol. 35, No. 11 https://doi.org/10.1016/j.pt.2019.08.007
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Glossary
11b-hydroxysteroid dehydroge-
nase: the two isozymes 11b-HSD1
and 11b-HSD2 catalyze the inter-
conversion of active cortisol and
corticosterone with inactive corti-
sone and 11-dehydrocorticoster-
one. 11b-HSD1 is expressed in
most cells and acts predominantly
as a reductase to catalyze the re-
activation of GCs. 11b-HSD2
mainly inactivates GCs to ensure
aldosterone agonism of the
mineralocorticoid receptor.
11b-HSD2 expression is largely
restricted to the distal nephron,
sweat and salivary glands, and
colonic epithelium.
A-ring reductases: hepatic
5a-reductase and 5b-reductase
yield dihydrometabolites of
endogenous GCs that are further
reduced to generate polar me-
tabolites that can be rapidly
cleared by the kidneys (Figure 2).
Adrenal gland: a gland located
above the kidney; it produces
several hormones. The outer cor-
tex synthesizes GCs, the mineral-
ocorticoid aldosterone, and an-
drogens. The inner medulla
synthesizes the catecholamines,
adrenalin, and noradrenalin.
Adrenalectomy: the surgical
removal of the adrenal glands.
Adrenocorticotropic hormone
(ACTH): a hormone secreted by
corticotroph cells of the anterior
pituitary in response to CRH.
ACTH binds to the melanocortin
receptor 2 on cells of the adrenal
cortex, leading to the synthesis of
GCs and, to a lesser extent,
aldosterone.
Corticosteroid-binding globulin
(CBG): also known as transcortin.
CBG is an alpha-globulin pro-
duced by the liver, which binds
and transports corticosteroids
and other steroid hormones.
Corticotropin-releasing hormone
(CRH): a hormone released by the
paraventricular nucleus of the hy-
pothalamus as part of a daily
circadian rhythm or a centrally
driven stress response. After
secretion, CRH reaches the ante-
rior pituitary where it regulates
ACTH secretion.
CRH stimulation test: a test of the
HPA axis function with adminis-
tration of CRH. This leads to ACTH
secretion by the pituitary and ad-
renal cortisol production.
Trends in Parasitologyinformation online). Because endogenous GCs exert various effects, their role in malaria is of great
interest and is discussed in this review. We start by introducing GCs and their effects, followed by
their role in murine malaria and the potential implications for human malaria.
Production and Clearance of Endogenous Glucocorticoids
Endogenous GCs, that is, cortisol in humans and corticosterone in rodents, regulate a wide range of
physiological processes. They are synthesized upon stimulation of the HPA axis [17] (Figure 1, Key
Figure). In normal conditions, the axis is stimulated in a circadian and pulsatile manner leading to
a GC peak in the morning in humans and in the evening in mice, due to opposite diurnal rhythms.
The HPA axis is further activated in conditions of stress – for example, psychological distress, physical
strain, tissue trauma, and inflammation – by both neural and nonneural routes [18,19]. Terminal nerve
endings of afferent autonomic nerves express several receptors that can sense pathogens or cyto-
kines in tissues. Cytokines such as IL-1b, tumor necrosis factor (TNF)-a, and IL-6 are potent inducers
of the HPA axis response. The resulting signaling is projected to the hypothalamus via autonomic
nuclei in the brainstem. Moreover, circulating inflammatory mediators can access brain sites via
circumventricular organs or via inflammation-mediated breakdown of the blood–brain barrier. The
paraventricular nucleus of the hypothalamus secretes corticotropin-releasing hormone (CRH),
consecutively leading to the secretion of adrenocorticotropic hormone (ACTH) or corticotropin by
the anterior pituitary gland (Figure 1). ACTH then stimulates the production of GCs by the adrenal
cortex. When the stress subsides, GCs finally exert a negative feedback on both CRH and ACTH
production.
The classical CRH–ACTH–GC axis is complemented by direct stimulation of the pituitary or adreno-
cortical cells. ACTH release from pituitary cells can be directly induced by IL-1, IL-2, or vasopressin
[20,21]. ACTH-independent induction of GC synthesis is possible by direct ligation of Toll-like recep-
tor 2 (TLR2) and TLR4 in adrenocortical cells [22]. GC synthesis or steroidogenesis from cholesterol
mainly originates in the adrenal cortex (Figure 2), although some production has also been reported
in the thymus, intestine, skin, and brain [23].
Of the cortisol/corticosterone that is released into the circulation, approximately 5% is free and thus
active, 20% is bound to albumin, and the remaining 75% is tightly bound to corticosteroid-binding
globulin (CBG) [24]. CBG is responsible for the systemic distribution of GCs and the delivery to tis-
sues. Neutrophil elastases can cleave CBG, and therefore more bioactive GCs might be liberated
at inflammatory sites [25].
The principal routes of cortisol clearance occur in the liver, through A-ring reductases, and in the kid-
ney, through 11b-hydroxysteroid dehydrogenase type 2 (11b-HSD2; Figure 2). The inactivation by
11b-HSD2 prevents high-affinity binding of GCs to the mineralocorticoid receptor (MR), to enforce
specific aldosterone binding. Within cells, the inactive cortisone or 11-dehydrocorticosterone is reac-
tivated by 11b-HSD1 into, respectively, cortisol or corticosterone. These enzymes contribute daily to
30–40% of the total cortisol turnover [26]. Whereas the expression of 11b-HSD2 is mostly restricted to
the distal nephron of the kidney, sweat and salivary glands, and colonic epithelium, 11b-HSD1 is
widely expressed and is regulated by inflammatory signals, including TNF-a and IL-1b [27]. GCs
furthermore induce 11b-HSD1 and suppress 11b-HSD2 expression, which in turn amplifies GC avail-
ability [27].
Endogenous Glucocorticoids Exert a Wide Range of Effects
GCs are lipophilic and diffuse easily through cell membranes. Once inside the cytosol, GCs bind to
the glucocorticoid receptor (GR), which is expressed by almost all nucleated cells (Figure 3). The GR
localizes in the cytoplasm in a multiprotein complex comprised of heat shock proteins, immunophi-
lins, and other chaperones [28]. When GCs bind to the receptor, liganded GR can translocate to the
nucleus to interact with DNA and other proteins as a monomer, homodimer, or even a tetramer
[25,29,30]. As a genuine transcription factor, GR activates or represses gene transcription of up to
20% of all genes, depending on the target tissue [25]. Besides the genomic effects that affectTrends in Parasitology, November 2019, Vol. 35, No. 11 919
Key Figure
Endogenous Glucocorticoids (GCs) Integrate the Regulation of
Immune, Metabolic, and Cardiovascular Homeostasis to Counteract
Pathophysiological Processes in Malaria
Dexamethasone suppression
test: a test of HPA axis function
with administration of dexameth-
asone, a synthetic GC. This leads
to an increased negative feedback
on the pituitary, resulting in lower
ACTH and lower cortisol plasma
levels.
Gluconeogenesis: generation of
glucose from precursors, mainly
lactate, alanine, or glycerol.
Gluconeogenesis especially takes
place in the liver and to a lesser
extent in the cortex of the kidneys.
Glycogen: a multibranched poly-
saccharide of glucose that repre-
sents the main storage form of
glucose, particularly present in
the liver and skeletal muscle.
Hypophysectomy: the surgical
removal of the pituitary gland or
hypophysis.
Hypothalamic–pituitary–adrenal
(HPA) axis: an interactive neuro-
endocrine unit that functions
through direct hormone stimula-
tion and feedback interactions,
key for basal homeostasis and
physiological responses to stress.
Malaria-associated acute respi-
ratory distress syndrome (MA-
ARDS): a severe respiratory
complication of malaria associ-
ated with alveolar inflammation,
damage to the alveolar-capillary
membrane, alveolar edema, and
severe hypoxemia, altogether
leading to a poor prognosis.
Metyrapone suppression test: a
test of the HPA axis function with
administration of metyrapone,
which inhibits adrenal cortisol
production. This leads to
increased ACTH plasma levels
due to less negative feedback on
the pituitary. Suboptimal ACTH
increases in this test are indicative
of HPA axis dysfunction.
Vasopressor: an agent that causes
a rise in blood pressure by
vasoconstriction.
(Figure legend at the bottom of the next page.)
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Figure 2. Adrenal Biosynthesis and Clearance of Glucocorticoids (GCs).
This scheme summarizes the synthesis of endogenousGCs from cholesterol in the adrenal cortex. Enzymatic conversions
are shown as arrows. ActiveGCs – corticosterone in rodents and cortisol in humans – are released into the circulation and
areeithercleared throughA-ring reductases in the liveror through11b-hydroxysteroiddehydrogenase type2 (11b-HSD2),
mainly in the kidney. The inactive cortisone or 11-dehydrocortisone that is generated by 11b-HSD2, is reactivated within
cells by 11b-HSD1 into, respectively, cortisol or corticosterone. Synthetic GCs are used in the treatment of various
disorders, including asthma, dermatitis, and rheumatoid arthritis. The drugs that are mentioned in this review are
depicted here. Abbreviations: 17a-OH preg, 17a-hydroxy-pregnenolone; 17a-OH prog, 17a-hydroxy-progesterone;
BMS, b-methasone hemisuccinate; DHEA, dehydroepiandrosterone; Preg, pregnenolone; Prog, progesterone.
Trends in Parasitologytranscription of target genes and take hours, also nongenomic effects of GCs have been described,
which manifest rapidly (seconds to minutes) and do not require protein synthesis [25,31]. Mechanisms
include intercalation of GCs into membranes, signaling through a membrane-bound GR, interaction
with cytoplasmic kinases, and induction of apoptosis by mitochondrial translocation of theFigure 1. The hypothalamic–pituitary–adrenal (HPA) axis is profoundly stimulated in conditions of stress, for
example, inflammation. Both neural and nonneural routes activate the paraventricular nucleus of the
hypothalamus that secretes corticotropin-releasing hormone (CRH), consecutively leading to the secretion of
adrenocorticotropic hormone (ACTH) by the anterior pituitary gland. ACTH in turn activates the production of
GCs by the adrenal cortex. GCs then exert a negative feedback on both CRH and ACTH production. GCs
influence many processes that are essential to survive systemic infections, including malaria. Their immune
modulating effects include the inhibition of leukocyte extravasation, proliferation, and activity, and interference
with downstream proinflammatory signaling and cytokine function. In malaria, the balance between immune-
mediated clearance of the parasite and inflammation dictates host survival and is coregulated by GCs. GCs
mediate metabolic effects, especially under stress or fasting conditions, by increasing circulatory glucose by
supporting gluconeogenesis, counteracting insulin, and decreasing peripheral glucose uptake. Hypoglycemia is
common in malaria and associates with a poor outcome. Malaria infection in mice suppresses gluconeogenesis,
and in the absence of GCs severe hypoglycemia occurs. GCs furthermore have vascular effects by preventing
vasodilatation, by supporting intravascular fluid retention, and by inhibiting endothelial activation. This might
also be important to limit pathogenicity in malaria, since severe malaria is associated with hemodynamic
instability (hypovolemia and hypotension), extensive endothelial activation, and loss of barrier function.
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Figure 3. The Glucocorticoid Receptor Influences Gene Expression by Several Molecular Mechanisms.
In its nonliganded state, the glucocorticoid receptor (GR, pink shape) is predominantly cytoplasmic and in complex
with chaperoning proteins. Upon binding corticosteroid ligand (filled black circle), GR accumulates in the nucleus,
where it influences gene expression as a transcription factor. By virtue of glucocorticoid response elements (GRE,
green), GR typically binds onto promoters of target genes as a dimer as onemechanism to activate its target genes.
Those include genes that contribute to gluconeogenesis but also anti-inflammatory genes. Target gene repression
can be consequent to direct GR binding onto so-called negative GRE elements (nGRE, red) on the DNA or by
means of protein–protein interactions, whereby GR can interfere with the activity of other transcription factors
(TF, orange shape). In case these transcription factors are proinflammatory [e.g., nuclear factor (NF)-kB,
activator protein 1 (AP-1)], the protein–protein interaction mechanism contributes to the anti-inflammatory
action of GR. It is still debated to what extent the protein–protein interaction mechanism relies in vivo on GR as
a monomer or a dimer. Please note that many variants of the simplified mechanisms that are represented here
are possible [100]. Abbreviations: DUSP1, dual-specificity protein phosphatase 1; F1,6-biPase, fructose-1,6-
biphosphatase; G6Pase, glucose-6-phosphatase; GILZ, glucocorticoid-induced leucine zipper; ICAM-1,
intercellular adhesion molecule-1; Il-6, interleukin 6; PEPCK, phosphoenolpyruvate carboxykinase; Sphk1,
sphingosine kinase 1; TNF-a, tumor necrosis factor alpha; VCAM, vascular cell adhesion molecule.
Trends in Parasitologyligand-bound GR. Furthermore, in several cell types expressing the MR but not 11b-HSD2, MR may
also bind GCs with high affinity and participate substantially in GC signaling [32]. GCs influence
many processes ranging from immunity to bone remodeling, cardiovascular function, reproduction,
cognition, and metabolism [33].
GCs are well known for their broad immune-modulating effects at multiple levels [25]. In summary,
GCs interfere with the downstream proinflammatory signaling of receptors sensing danger signals
(pattern-recognition receptors, complement receptors, and Fc receptors). Furthermore, GCs prevent
vasodilatation and increased vasopermeability, which are defined hallmarks of inflammation. They922 Trends in Parasitology, November 2019, Vol. 35, No. 11
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specific way, for example, by inducing apoptosis and changing their differentiation fate or altering
their function [34]. GCs are mostly anti-inflammatory, especially during ongoing inflammation or con-
cerning the adaptive immune system. However, proinflammatory effects have been described as well,
and they include the upregulation of the expression of NLRP3 and TLRs. This immune-priming role
might be important under basal conditions, when GC levels are low, and during the early stages of
inflammation, which are controlled by the innate immune response [24,25,31,35,36].
Besides their effects on the immune response, GCs synergize with catecholamines, glucagon, and growth
hormone to mediate metabolic effects. The leading metabolic effect of GCs under stress or fasting con-
ditions is the ability to increase circulatory glucose to ensure survival and to provide energy to the brain.
GCs mediate the elevation of glucose levels via: (i) increased gluconeogenesis; (ii) decreased peripheral
glucose uptake; (iii) mobilization of lipids and amino acids through lipolysis and proteolysis; and (iv) coun-
teracting insulin signaling [37]. The pathophysiological consequences of endogenous or exogenous GC
excess include hyperglycemia, insulin resistance, fatty liver, obesity, and muscle wasting [37].Endogenous Glucocorticoid Levels Are Increased in Malaria
The results from studies on GCs in human malaria are summarized and referred to in Table S1. In
patients infected with Plasmodium vivax and Plasmodium falciparum, circulating GC levels are higher
compared with healthy controls. Although controversial, GC levels appear higher in patients with CM
compared with UM. Cortisol levels decline during treatment as the clinical symptoms and parasitemia
decrease. Cortisol levels also increase upon malaria infection of pregnant women. Furthermore, preg-
nancy-induced cortisol increases might contribute to the higher vulnerability of pregnant women to ma-
laria. This seems particularly the case in primigravidae, in whom cortisol levels, the likelihood of infection,
and parasitemia are higher compared with multigravidae. Cortisol levels seem to correlate positively with
higher serum IL-10 levels and parasitemia, at least in primigravidae. Interestingly, the increase inGC levels
upon malaria infection is conserved, as it was also observed in mice, birds, and lizards [38,39].Endogenous Glucocorticoids Are Essential for Surviving Malaria and Sepsis
Following decades of intense investigation, gathered insights on the protective effects of endoge-
nous GCs in bacterial sepsis may serve as an example for severe complications in other infectious
diseases, including malaria. As indicated in Box 1, SM and sepsis are complex multisystem disorders
that share some important clinical characteristics [40]. For instance, a combination of inflammatory
and metabolic disturbances is observed in both diseases. GCs are regulators of immunity as well
as metabolism, and therefore GC features are likely to show some overlap in malaria and sepsis.Box 1. Similarities between Severe Malaria and Septic Shock
In this review, GC and HPA axis function are compared between severe malaria and septic shock, because both
conditions present a number of important similarities. Both are characterized by potent inflammatory re-
sponses (including increased cytokines, e.g., TNF-a), endothelial activation and vascular permeabilization,
increased GC levels, coagulopathy, and a number of organ-specific complications including damage to the
brain, lungs, kidneys, and liver. Cardiovascular collapse with hypotension and hypovolemia are cardinal fea-
tures of septic shock and are also present in a subset of SM patients (‘algid malaria’). Metabolic abnormalities,
including hyperlactatemia and hyper- or hypoglycemia are also common in both diseases. Some important dif-
ferences between severe malaria and septic shock relate to the etiology. Malaria-infected erythrocytes cytoad-
here to the vascular endothelium and thereby directly cause vascular obstruction, which is thought to be one of
the main pathogenic mechanisms. The pathogenesis of septic shock is rather related to the potent activation of
inflammatory responses through direct stimulation of Toll-like receptors (TLRs) by bacterial products such as
LPS. Malaria parasites are less potent activators of TLRs, although some components, for example, malarial
glycosylphosphatidylinositol anchors, also activate TLRs and inflammation is also involved in SM. Furthermore,
both conditions might co-occur, since malaria infection also predisposes to bacteremia, for example, with non-
typhoid Salmonella.
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ment reverses the effect of adrenalectomy in both conditions [41–47].
In sepsis, among the adrenal hormones, GCs are essential mediators of tolerance. Hypophysectomy
increases mortality from lipopolysaccharide (LPS)-induced shock [45]. When only the adrenal medulla
was surgically removed, mortality from sepsis was unaffected in contrast to observations after com-
plete adrenalectomy [48]. Also, the nonselective inhibitor of the GR, mifepristone (RU486), reduces
survival in sepsis or renders the endotoxin-resistant TLR4-mutant C3H/HeJ mice sensitive to endo-
toxin [49,50]. Similarly, the SPRET/Ei mice that are resistant to a lethal dose of LPS, were sensitized
to LPS by RU486 or adrenalectomy [51]. The LPS-resistant phenotype of SPRET/Ei mice is attributed
to higher GR expression, a basal overactivation of the HPA axis and higher levels of the glucocorti-
coid-induced leucine zipper (GILZ) [51,52]. Similarly, GR overexpression enhances the resistance to
endotoxic shock [53]. Moreover, dimerization of the GR is required tomediate survival after cecal liga-
tion and puncture (CLP) and LPS-induced sepsis [54].
In contrast to data in sepsis, the functional role of GCs in malaria has received little attention. The
increased levels of corticosterone in murine models of malaria correlated with parasitemia and
severity of infection (Table S2). It was shown in the 1980s that in Plasmodium berghei K173-infected
immunized Swiss mice, pregnancy-associated increases in corticosterone levels caused a loss of ma-
larial immunity and more recrudescences. Even before that, two limited studies reported that adre-
nalectomy reduced survival in malaria, though nomechanisms were explored (references in Table S2).
In light of the delicate balance in immune andmetabolic responses during malaria and the regulation
of both processes by endogenous GCs, our group investigated the role of endogenous GCs in exper-
imental malaria. The GC-reactivating enzyme, 11b-HSD1, modulates parasitemia, clinical disease
score and plasma cytokine levels, depending on the parasite strain, but is not crucial for survival
[55]. Knock-out of the 11b-HSD1 gene specifically abolishes the conversion of inactive GCs into their
active forms in peripheral cells and tissues. It also results in a decreased negative feedback to the HPA
axis and a subsequent increased adrenal production of GCs, leading to maintained or even elevated
levels of circulating active corticosterone, hence explaining the mild phenotype [26,56,57].
In contrast, adrenalectomy drastically abrogates the induction of GCs upon stress. The effects of
adrenalectomy were studied in four distinct mouse models of malaria [47]. Adrenal hormones were
found to confer disease tolerance in malaria, since they protect against early death without affecting
parasitemia. Treatment with a synthetic GC (dexamethasone) prevented lethality, strongly suggest-
ing GCs as the main tolerance-mediating adrenal hormones, although the contribution of other
adrenal hormones (e.g., aldosterone and/or catecholamines) cannot be ruled out. Interestingly,
plasma GC levels were recently found to be associated with tolerance to malaria and other haemo-
sporidian parasites in a wild bird population, suggesting conservation of this tolerance mechanism
throughout evolutionary phyla [38].Homeostatic Properties of Endogenous GCs during Infection
Endogenous GCs have many homeostatic properties that are essential to survive stressful conditions,
such as a severe systemic infection. They promote survival via anti-inflammatory, gluconeogenic, and
vascular effects (Figure 1).Anti-inflammatory Functions
A functional GR suppresses inflammation withinmultiple or specific cell types, thereby contributing to
survival from infection. Lethality after adrenalectomy during endotoxemia or malaria is accompanied
by elevated levels of cytokines in the circulation and brain [45,47,58–60]. Full GR dimerization abilities
are required for survival from CLP- and LPS-induced sepsis via downregulation of IL-1b in macro-
phages [54]. GC-mediated inhibition of p38 mitogen-activated protein kinase (MAPK) and upregula-
tion of sphingosine kinase 1 (Sphk1) in macrophages are also required to suppress LPS-induced
inflammation and lethality [61,62]. Knockout of the endothelial GR in septic mice increases mortality,924 Trends in Parasitology, November 2019, Vol. 35, No. 11
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uously interpreted since the Tie1 promotor, used to generate these mice, is also expressed in
hematopoietic cells [64]. Furthermore, hepatic GR prevents mortality in septic mice via the inhibition
of hepatic inflammation [63,65]. Dendritic cell (DC)-specific deletion of the GR rendered mice highly
susceptible to LPS-induced septic shock, with increased inflammatory cytokines, hypothermia, and
mortality [66]. The protective effect of GCs appeared mediated via suppression of IL-12 production
by CD8+ DCs, which is also essential to promote tolerance to subsequent challenges. In natural killer
(NK) cells, GCs inhibit interferon (IFN)-g and induce programmed cell death protein-1 (PD-1) expres-
sion to promote tolerance to LPS and to viral infections [67,68]. Overall, these studies indicate that
endogenous GC signaling through the GR is essential to avoid exaggerated inflammation upon
infectious stimuli. In malaria, the balance between the immune system and parasite growth and im-
mune-evasion is critical and dictates whether the host survives [2]. This balance is determined by pro-
and anti-inflammatory cytokines such as IL-12, IFN-g, and IL-10, and inhibitory receptors such as PD-1.
Conceivably, GCs appear crucial to maintain a balanced host response upon malaria infection. This is
corroborated by the increased inflammation in malaria-infected adrenalectomized (Adx) mice [47].Glucose Homeostasis
Importantly, GCs support gluconeogenesis. Besides stress-induced hyperglycemia, also sponta-
neous hypoglycemia occurs in sepsis and is associated with a higher mortality compared with iatro-
genic hypoglycemia that results from intensive insulin therapy [69,70]. In early studies in septic mice, it
is reported that an initial hyperglycemic state is followed by hypoglycemia [71]. Results from old
studies in mice indicate that endotoxemia reduces liver glycogen stores and glycogen synthase ac-
tivity and lowers the activities of gluconeogenic enzymes, including phosphoenolpyruvate carboxy-
kinase, fructose-1,6-biphosphatase, and glucose-6-phosphatase [71–75]. In this already highly
challenged metabolic state, adrenalectomy leads to severe lethal hypoglycemia [48,71]. Witek-Janu-
sek et al. reported that removal of the adrenal medulla exacerbated the hypoglycemia seen in normal
endotoxin-treated rats. However, this was not as pronounced as in Adx rats, in which severe hypogly-
cemia coincided with hyperlactacidemia and depletion of liver glycogen [48]. Inhibition of hepatic GR
with short hairpin RNA blunted the hyperglycemic stress response after induction of sepsis in mice
[65]. Importantly, both hyper- and hypoglycemia occur frequently in severe malaria patients, with hy-
poglycemia associated with a poor outcome [3,76]. Exhaustion of glycogen stores and insufficient
gluconeogenesis may thus be a prominent cause of the observed hypoglycemia, and this is further
supported by the finding that fasting and infection-induced anorexia enhance the risk of hypoglyce-
mia in malaria [3,5]. Our preclinical data suggest that adrenal hormones, andmost likely GCs, are crit-
ical regulators of glucose homeostasis in malaria, since adrenalectomy results in lethal hypoglycemia
and hepatic glycogen exhaustion in malaria mouse models [47]. Glucagon levels were in line with a
normal counter-regulatory increase, whereas the transcription of hepatic gluconeogenic enzymes
remained unaltered in infected Adx mice. The marked hypoglycemia was not prevented or reversed
by glucose administration, TNF-a neutralization, or administration of clonidine, an a2-adrenergic
agonist, which potently inhibits pancreatic insulin release [47]. In contrast, treatment with dexameth-
asone prevented the hypoglycemia, lowered cerebral cytokine expression, and significantly
increased survival rates. Interestingly, this was not accompanied by the induction of gluconeogenic
enzyme expression, suggesting that dexamethasone may mediate its protective effect mainly via
the inhibition of excessive inflammation [47].Vascular Effects
Adrenal hormones co-regulate the cardiovascular response, a phenomenon that possibly plays a
crucial role in the vasopressor function during malaria. Cortisol enhances the vasoactive tone via
the retention of intravascular fluid and stimulation of ionotropic and vasopressor responses to cate-
cholamines and angiotensin II [21]. Sepsis is often characterized by a decreased response to catechol-
amines. This is thought to be due to desensitization or downregulation of the catecholamine recep-
tor, which can be prevented by GCs [77]. Studies in Adx rodents, including complementation by
dexamethasone, supported the essential role of GCs in controlling the vasopressor response during
sepsis [78–80]. Adrenal hormones thus mediate additional tolerance to LPS by preventing severeTrends in Parasitology, November 2019, Vol. 35, No. 11 925
Trends in Parasitologycirculatory shock, characterized by the fall in blood pressure and vascular hyporeactivity to catechol-
amines. Several mechanisms seem to explain this protective effect by adrenal hormones, including
an inhibition of nitric oxide (NO) synthesis and cyclooxygenase, rapid potentiation of catecholamine
effects on mesenteric arteries, and induction of glutamine synthase, which indirectly maintains
nitrogen homeostasis [78–82]. In addition, endothelial deletion of the GR coincides with more hemo-
dynamic instability, elevated NO levels, and increased mortality after LPS administration [63]. In ma-
laria, hypovolemia is common, and hypotension (‘algid malaria’) occurs in a proportion of patients
[83]. Interestingly, in one study, low cortisol levels were found in hypotensive malaria patients [84].
GCs may thus protect malaria patients against hemodynamic instability, but further studies are
required. Importantly, extensive endothelial activation is observed in malaria, often with increased
barrier dysfunction and edema [85]. GCs have potent protective effects on endothelial cells by
decreasing the expression of inflammation-related proteins and by increasing junctional molecules,
thereby preserving the barrier function of the endothelium [86]. This suggests that endogenous GCs
might be important to limit the endothelial damage in malaria, although the induction of glucocor-
ticoid resistance by parasite products and cytokines may interfere with this protective effect [87].
Does a Dysfunctional HPA Axis Contribute to Disease Severity in Human Malaria?
Although critically ill patients mostly show a pronounced rise in cortisol, some patients seemingly
have insufficient cortisol available to cope with high illness-related stress, denoted as critical
illness-related corticosteroid insufficiency (CIRCI; previously labelled as relative adrenal insufficiency)
(Box 2) [88–90].
Several older studies investigated the HPA axis in malaria patients, and the data are summarized in
Table S1. In both UM and SM, mean cortisol levels appeared increased but ACTH remained within
or below the control range. This is consistent with reduced cortisol elimination rate, as measured inBox 2. Critical Illness-Related Corticosteroid Insufficiency (CIRCI), a Controversy
As malaria shares important characteristics with critical illness, particularly with sepsis, insights into the func-
tioning of the HPA axis in critically ill patients may guide further research and advance insight into the field
of malaria. However, there is still a lot of controversy surrounding HPA axis (dys)function in critical illness,
and recent studies have challenged classical dogmas [89,90,99].
Critical illness is a condition of extreme physical and inflammatory stress in which cortisol levels rise proportion-
ately with the severity of illness. This rise is considered vital to avoid shock and organ failure, to combat infec-
tions, and to repair tissue damage. The high cortisol levels were long assumed to result from a several-fold
increase in ACTH-driven cortisol production. However, ACTH rapidly decreases, and recent evidence showed
that the cortisol production rate is not, or only moderately, increased. Instead, cortisol metabolism appeared
strongly decreased, largely explaining the hypercortisolemia.
In certain patients, particularly the sickest (e.g., with septic shock), high amounts of cortisol produced by a
maximally activated adrenal cortex seemingly may not be large enough to cope with the severe stress of
the illness, denoted as ‘critical illness-related corticosteroid insufficiency’ (CIRCI, previously labeled ‘relative
adrenal insufficiency’). An abnormally low total cortisol response to an ACTH stimulation test has been sug-
gested to diagnose CIRCI and to identify patients who would benefit from hydrocortisone treatment in a
so-called stress dose of approximately 200 mg/day. However, this concept appeared problematic. First, the
ACTH stimulation test proved unreliable for assessing adrenocortical integrity or functional reserve. Indeed,
a low total cortisol response to ACTH was shown to result from an increased cortisol distribution volume
and low levels of cortisol-binding proteins, whereas free cortisol responses were normal or even higher than
normal. Second, advised stress doses of hydrocortisone, equivalent to a six to ten fold increased cortisol
production, do not consider the five to eight fold increased half-life of cortisol in critical illness and thus are
probably too high, possibly increasing central adrenocortical suppression via feedback inhibition. The long-
term safety for physical and neurocognitive functioning of such doses has not been proven. Third, treatment
of septic shock patients with stress doses of hydrocortisone did not show a uniform survival benefit, although
time to shock reversal, and weaning from mechanical ventilation, was mostly shortened. Clearly, careful inves-
tigation of these issues is needed. Also in malaria, these issues may play a crucial role and may be different for
the specific complications of malaria.
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Outstanding Questions
Do aldosterone and/or catechol-
amines contribute to the tolerance
in malaria by enhancing the meta-
bolic and anti-inflammatory effects
of GCs?
Do GCs limit endothelial damage
and protect from hemodynamic
instability in malaria?
Does corticosteroid insufficiency
occur in malaria patients?
Does corticosteroid insufficiency
contribute to severity or specific
complications in malaria?
Can GC therapy be beneficial for a
subset of patients with severemalaria
and corticosteroid insufficiency?
Trends in ParasitologySM patients [91]. In UM, both the metyrapone suppression test and the dexamethasone suppres-
sion test indicated a normal pituitary response, suggestive of an intact HPA axis [92,93]. In contrast,
a CRH stimulation test revealed a suppressed pituitary response with low ACTH secretion in SM
patients, which is indicative of a suboptimal HPA axis function [91]. Furthermore, the finding that
cortisol is not increased in all SM patients [84,91] does suggest that CIRCI may occur in a subset
of SM patients, possibly related to specific complications. As suggested by mouse models of ma-
laria, disturbances in the HPA axis response might cause a loss of tolerance and the development
of severe hypoglycemia and hyperinflammation in malaria. Whether this occurs in malaria patients
and whether such patients might benefit from GC therapy to restore homeostasis requires further
investigation.
Importantly, two clinical trials in the 1980s failed to show clinical benefit of GCs for patients with CM
(Table S1). During the first trial in Thailand by Warrell et al., 50 P. falciparum-infected patients with
comatose CM were administered quinine and dexamethasone [2 mg/kg; intravenously (IV)] [94].
Dexamethasone had no effect on overall survival, and coma was even prolonged in some survivors.
In the second, smaller study in Indonesia, Hoffman et al. used quinine and a higher dosage of dexa-
methasone (11.4 mg/kg; IV) in 18 CM patients and confirmed the lack of benefit, but did not detect
deleterious effects [95]. Although Warrell et al. stated that complications such as pneumonia and
gastrointestinal bleeding occurred more often in treated patients, a meta-analysis of both trials
did not show significant differences [96]. Important to note is that, in both trials, all patients were
treated with the antimalarial drug quinine. Quinine is known to induce hypoglycemia by insulin
secretion, which may have masked the potential positive metabolic effects of dexamethasone
[97,98].
Despite the apparent failure of dexamethasone to help patients with CM, one of the most fulminant
complications, the therapeutic impact on larger patient numbers and other complications that have
a broader therapeutic window remains unknown. With the caveat in mind that differences in path-
ophysiology between mice and patients cannot be excluded, it is important to note that GCs have
beneficial effects against malaria-associated pathologies in mice (Table S2). Early dexamethasone
treatment (before neurological symptoms appear) protected mice from lethal CM, inhibited hypo-
thermia and pathological changes in various organs (brain, liver, lung, spleen, kidney) and reduced
vascular permeability. Administration of a liposome-encapsulated formulation of the GC prodrug
b-methasone hemisuccinate (BMS) upon PbANKA infection, reduced the toxicity and increased
the efficacy compared with free BMS. It prevented CM and lowered edema, hemorrhages, and
mRNA expression of IFN-g, TNF-a, CCL2, CCL5, CXCL9, and intercellular adhesion molecule 1
(ICAM-1). Also, a decreased activation of microglia and astrocytes was found. In a murine model
of MA-ARDS (PbNK65-infected C57BL/6 mice), high doses of dexamethasone blocked the lung
pathology, even when administered after appearance of the complication. This was paralleled
by reduced pulmonary leukocyte accumulation and expression of IFN-g and CCL2 (references in
Table S2).
Overall, limited indications suggest that HPA axis dysfunctionality may occur in a subset of SM pa-
tients. More research is needed to define this subset, to evaluate whether it might be possible to
translate the promising findings on GC treatment of experimental murine malaria into patients.
Concluding Remarks
GCs have pleiotropic activities on almost all cell types and are increased in sepsis and malaria. Over-
all, the essential roles of GCs for disease tolerance and survival during both malaria and sepsis most
probably involve a balanced combination of their anti-inflammatory, glucometabolic, and vascular
effects. Disruption of the HPA axis in murine malaria models results in increased inflammation and
lethal hypoglycemia, and this can be rescued by exogenous GC treatment [47]. Treatment with dexa-
methasone may thus improve survival in the case of a failing HPA axis. However, translation to the
human patient setting may be more complex than one assumes, considering the conflicting results
and controversy that go along with GC treatment of CIRCI patients. Limited data suggest that
possible dysfunctions of the HPA axis might occur in malaria patients, and that this may contributeTrends in Parasitology, November 2019, Vol. 35, No. 11 927
Trends in Parasitologyto severity and/or specific complications, but further documentation is required (see Outstanding
Questions). Although the failed clinical trials of dexamethasone against CM in the past have
decreased the interest in GCs in malaria, more research in this field is warranted. More in-depth
studies of patient subpopulations with HPA dysfunctions might possibly clarify whether some SM
patients may benefit from GC therapy.
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